Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Blood (2025) 146 (Supplement 1): 6065.

https://doi.org/10.1182/blood-2025-6065

Published: 2025

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

Impact of graft versus host disease prophylaxis with post transplant cyclophosphamide on the prognostic value of HCT-CI

Ansh Mehta, Haesook Kim, Arcita Pramudita, Deborah Liney, Remy Dulery, Vincent Ho, Corey Cutler, John Koreth, Mahasweta Gooptu, Joseph Antin, Amar Kelkar, Sarah Nikiforow, Prashant Nageshwar, Catherine Wu, Jerome Ritz, Rizwan Romee, Robert Soiffer, Roman Shapiro

Blood (2025) 146 (Supplement 1): 4227.

https://doi.org/10.1182/blood-2025-4227

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia

Brian Ball, Mahasweta Gooptu, Ling Li, Christopher Hourigan, Sally Mokhtari, Dongyun Yang, Leonardo Farol, Yazeed Samara, Anthony Selwyn Stein, Guido Marcucci, Monzr M. Al Malki, Corey Cutler, Ryotaro Nakamura, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 5207.

https://doi.org/10.1182/blood-2025-5207

Published: 2025

Journal Articles

Effect of graft cellular content on outcomes in HLA mismatched hematopoietic cell transplantation using post-transplant cyclophosphamide

Remy Dulery, Sandra Lee, Sarah Nikiforow, Carol Reynolds, Heather Garrity, Karl Stasko, Andrew Mason, Corey Cutler, John Koreth, Mahasweta Gooptu, Joseph Antin, Amar Kelkar, Vincent Ho, Catherine Wu, Rizwan Romee, Jerome Ritz, Robert Soiffer, Roman Shapiro

Blood (2025) 146 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2025-4260

Published: 2025

Journal Articles

Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML

H. Moses Murdock, Kyle Hebert, Jennifer Brock, Elise Auriemma, Felicia Lim, Jeremy Ryan, Mahasweta Gooptu, Roman Shapiro, Corey Cutler, Amar Kelkar, Vincent Ho, Denbaa Bat-Erdene, Anthony Letai, Jerome Ritz, R. Coleman Lindsley, Joseph Antin, Robert Soiffer, Jacqueline Garcia

Blood (2025) 146 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2025-4206

Published: 2025

Journal Articles

How I treat AML relapse after allogeneic HSCT

Mahasweta Gooptu, H. Moses Murdock, Robert J. Soiffer

Blood (2025) 145 (19): 2128–2137.

https://doi.org/10.1182/blood.2024025705

Published: 2025

Journal Articles

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

H. Moses Murdock, Haesook T. Kim, Katie Maurer, Amar H. Kelkar, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Corey S. Cutler, John Koreth, Jerome Ritz, Joseph H. Antin, Vincent T. Ho, Sarah Nikiforow, Catherine J. Wu, Robert J. Soiffer

Blood (2024) 144 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2024-204343

Published: 2024

Journal Articles

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Blood (2024) 144 (Supplement 1): 379.

https://doi.org/10.1182/blood-2024-200128

Published: 2024

Journal Articles

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Roman M. Shapiro, Haesook T. Kim, William H Terral, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Joseph H. Antin, Katie Maurer, Catherine J. Wu, Robert Zeiser, Jerome Ritz, Robert J. Soiffer, Sarah Nikiforow, John Koreth

Blood (2024) 144 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2024-194102

Published: 2024

Journal Articles

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Jeffery J. Auletta, Steven M. Devine, Heather E. Stefanski, Stephen R. Spellman, Todd E. Defor, Brent R. Logan, Brandan J. Butler, Mahasweta Gooptu, Brian C. Shaffer, Antonio M. Jimenez Jimenez, Sameem Abedin, Dipenkumar Modi, MHD Monzr M. Al Malki, Rachel J. Cook

Blood (2024) 144 (Supplement 1): 3514.1.

https://doi.org/10.1182/blood-2024-198252

Published: 2024

Journal Articles

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Blood (2024) 144 (Supplement 1): 3500.

https://doi.org/10.1182/blood-2024-199776

Published: 2024

Journal Articles

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Jacqueline S. Garcia, Haesook T. Kim, Jennifer Brock, H. Moses Murdock, Mahasweta Gooptu, Vincent T. Ho, Roman M. Shapiro, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Denbaa Bat-Erdene, Jeremy Ryan, Anna Bosch-Vilaseca, Anthony G. Letai, Jerome Ritz, Coleman Lindsley, Robert J. Soiffer, Joseph Antin

Blood (2024) 144 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2024-194170

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Michela Ansuinelli, Haesook T. Kim, Carol G. Reynolds, Francesco Malfona, Shuntaro Ikegawa, Rakuyo Tamada, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, John Koreth, Vincent T. Ho, Corey S. Cutler, Joseph H. Antin, Leslie Kean, Robert J. Soiffer, Jerome Ritz

Blood (2024) 144 (Supplement 1): 1041.

https://doi.org/10.1182/blood-2024-201835

Published: 2024

Journal Articles

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Jessica S. Little, Kyle Hebert, Donna S. Neuberg, Sarah Nikiforow, Mahasweta Gooptu, Roman M. Shapiro, John Koreth, Joseph H. Antin, Corey S. Cutler, Robert J. Soiffer, Jerome Ritz, Rizwan Romee, Vincent T. Ho, Nicolas C Issa, Lindsey R. Baden, Remy Dulery, Susan E Prockop

Blood (2024) 144 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2024-205169

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Impact of graft versus host disease prophylaxis with post transplant cyclophosphamide on the prognostic value of HCT-CI

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia

Effect of graft cellular content on outcomes in HLA mismatched hematopoietic cell transplantation using post-transplant cyclophosphamide

Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML

How I treat AML relapse after allogeneic HSCT

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only